Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Dermatology

Journal Scan / Research · April 27, 2022

Th2 IL-4/IL-13 Dual Blockade With Dupilumab Is Linked to Some Emergent Th17 Type Diseases

Journal of Investigative Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Investigative Dermatology
Th2 IL-4/IL-13 dual blockade with Dupilumab is linked to some Emergent Th17 type Diseases including seronegative arthritis, enthesitis/enthesopathy, but not humoral autoimmune diseases
J Invest Dermatol 2022 Apr 05;[EPub Ahead of Print], C Bridgewood, M Wittmann, T Macleod, A Watad, D Newton, K Bhan, H Amital, G Damiani, S Giryes, NL Bragazzi, D McGonagle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading